Revolution Medicines, Inc. (RVMD) - Stock Analysis
Last updated: Apr 13, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Pivotal Phase 3 daraxonrasib data showing a large OS benefit in PDAC plus nine AACR presentations (2026â04â17â04â22) and a justâpriced $1.5B equity + $500M convert raise have created a >50% rally and very high event density in the next week, giving RVMD significant shortâterm upside for traders willing to accept dilution and biotech volatility.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Zero revenue ⢠Large cash burn RVMD shows strong liquidity and low leverage but no revenue, massive R&D-driven losses and cash burn, and a market price far above tangible bookâimplying high downside risk absent a clear path to revenue or profitability.
Price Behavior
Key Price Behavior Insights: ⢠Single-day spike ⢠Breakout above range ⢠Extended/overbought Support Level: $92.50; $94â$100 Resistance Level: $134.37 RVMD experienced a fast breakout last monthâclose rose from $94.86 to $134.37 (~40%) driven by a single extreme oneâday spike, leaving the stock extended above the $94â$100 consolidation and vulnerable to a sharp pullback or gapâfill.
Sentiment & News
Key News Insights: ⢠Phase 3 win ⢠Big share jump ⢠Institutional buying Revolution Medicines' positive Phase 3 daraxonrasib dataâreportedly nearly doubling survival and cutting death risk ~60%âtriggered a ~35â38% share surge and record high while prompting institutional buying and analyst Buy consensus despite prior insider selling and short-term weakness.
AI Summary
Revolution Medicines' positive Phase 3 for daraxonrasib materially deârisks the company by converting its lead asset into a nearâterm commercial opportunity, but investors should treat the rerate as executionâdependentâmonitor regulatory filing/timing, early launch uptake and payer coverage, and the likelihood/timing of further financing that could dilute returns.
Description
Revolution Medicines is a clinical-stage precision oncology company developing small-molecule therapies that target RAS-driven cancers. Its pipeline includes a Phase 1/2 SHP2 inhibitor (RMC-4630) and multiple agents that selectively inhibit SOS1, mTORC1 signaling, and various oncogenic RAS(ON) mutants. The company has a collaboration with Sanofi on SHP2 programs, was founded in 2014, and is headquartered in Redwood City, California.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Apr 15 | Apr 22 | RVMD | Revolution Medicines, Inc. | Pivotal Phase 3 daraxonrasib data showing a large OS benefit in PDAC plus nine AACR presentations (2026â04â17â04â22) and a justâpriced $1.5B equity + $500M convert raise have created a >50% rally and very high event density in the next week, giving RVMD significant shortâterm upside for traders willing to accept dilution and biotech volatility. | Active | -2.6% |